Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 15/20 | 0.82 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.82 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380444 | 1.00 | ERBB2 (0.82) | ERBB2MINK1MAOBFFAR1CHRNB2 | |
| Mubritinib SCHEMBL571874 | 0.90 | ERBB2 (1.00) | ERBB2MINK1 | |
| Mubritinib SCHEMBL94943 | 0.90 | ERBB2 (1.00) | ERBB2MINK1 | |
| Mubritinib SCHEMBL6758911 | 0.90 | ERBB2 (0.98) | ERBB2MINK1 | |
| Mubritinib SCHEMBL6758913 | 0.90 | ERBB2 (0.98) | ERBB2MINK1 | |
| SCHEMBL26316653 | 0.88 | ERBB2 (0.70) | ERBB2MINK1MAOBFFAR1 | |
| SCHEMBL6579812 | 0.88 | ERBB2 (0.95) | ERBB2MINK1 | |
| SCHEMBL6579814 | 0.88 | ERBB2 (0.95) | ERBB2MINK1 | |
| SCHEMBL5759422 | 0.88 | ERBB2 (0.80) | ERBB2MINK1FFAR1 | |
| SCHEMBL5759417 | 0.88 | ERBB2 (0.80) | ERBB2MINK1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111886234-B | Heterocyclic mitochondrial activity inhibitors and uses thereof | 蒙特利尔大学 | 2023-12-15 | — | — | CN | disclosed |
| CN-111886234-A | Heterocyclic mitochondrial activity inhibitors and uses thereof | 蒙特利尔大学 | 2020-11-03 | — | — | CN | disclosed |
| US-7247649-B2 | Oxazoles, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1656371-A2 | NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005016921-A2 | NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038091-A1 | Novel oxazoles, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038091-A1 | Novel oxazoles, their manufacture and use as pharmaceutical agents | OXA1L, CYP11B2, RORB | ERBB2 944/4885MINK1 1364/4885MAOB 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.